Проблемы почечно-клеточного рака: отчет о конгрессе CORE


Попов А.М., Калпинский А.С.

ФГБУ "Медицинский радиологический научный центр" МЗ и СР РФ, Обнинск. ФГУ МНИОИ им. П.А. Герцена Минздравсоцразвития России, Москва.
Представлена информация об основных докладах Конгресса, посвященных лечению распространенного почечно-клеточного рака (ПКР). Были затронуты вопросы применения антиангиогенных препаратов (бевацизумаб, сунитиниб, пазопаниб, сорафениб) и ингибиторов mTOR (эверолимус, темсиролимус), представлены данные об использовании при метастатическом ПКР новых ингибиторов тирозинкиназ, изучаемых в клинических испытаниях (довитиниб и др.). Представлены данные о побочных эффектах таргетной терапии ПКР, путях их профилактики и лечения.

Литература


1. Tortora G. Molecular Signaling Pathways in mRCC and New Treatment Strategies. Conference of renal cancer experts. 8 apr 2011.


2. Calvo E. Biomarkers of Patient Response in Advanced RCC: Can We Predict Therapeutic Efficacy? Сonference of renal cancer experts. 8 apr 2011.


3. Porta C, Paglino C, De Amici M, et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinaseassociated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010;77(9):809–15.


4. Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26(15):abstr5046.


5. Figlin RA. Clinical Updates: VEGFR-TKI Treatment in mRCC. Conference of renal cancer experts. 8 apr 2011.


6. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26:abstr5123.


7. Di Lorenzo G, Carteni G, Autorino R, et al. Phase II study of sorafenib in patients with sunitinibrefractory metastatic renal cell cancer. J Clin Oncol 2009;27:4469–74.


8. Oudard S. The Role of mTOR Inhibitors in RCC Management. Conference of renal cancer experts. 8 apr 2011.


9. Mulders PFA. The Role of Immunotherapy in RCC. Conference Of Renal cancer Experts. 8 apr 2011


10. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicenter, open-label, randomised phase III trial. Lancet 2008;372:145–54.


11. Ravaud A. Safety Issues in RCC Treatment: Applying the Data to Clinical Practice. Conference of renal cancer experts. 9 apr 2011.


12. Bamias A. Patient-focused Care: Treating Through Co-morbidities. Conference of renal cancer experts. 9 apr 2011.


13. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon (IFN)-alfa in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:3584–90.


14. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.


15. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010;28: 1061–68.


16. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103–11.


17. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204–12.


18. Negrier S. Novel Therapies in RCC: Looking Beyond VEGF and mTOR. Conference of renal cancer experts. 9 apr 2011.


19. Angevin E, Lin C, Pande AU, et al. A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010;28(15):3057.


20. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010;16:311–19.


21. Bellmunt J. Ongoing and Future Clinical Trials: Addressing Unmet Needs in RCC. Conference of renal cancer experts. 9 apr 2011.


22. Ljungberg B, Cowan N., Hanbury DC, Hora M. et al. Guidelines on renal cell carcinoma 2011. European Association of Urology.


23. NCCN clinical practice guidelines in oncology 2011: kidney cancer. National Comprehensive Cancer Network.


Похожие статьи


Бионика Медиа